SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Myriad Genetics shares fall 6.2% after Piper Sandler downgrade

Myriad Genetics shares fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, saying major strategic action is likely needed.

MYGN

Shares of genetic testing company Myriad Genetics NASDAQ:MYGN fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, saying major strategic action is likely needed. Piper Sandler analyst Dave Westenberg downgraded Myriad Genetics by two steps.

Related stories